Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 25s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Gastro Retentive Drug Delivery Systems (Grdds)- Comprehensive Review

S. Martin[1], I. Soma Sundaram[*2]

[1]Research Scholar, Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai-600117, Tamil Nadu, India

Email ID: aishvinn@gmail.com

[2]Professor, Department of Pharmaceutics, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai-600117, Tamil Nadu, India

Email ID: ssundaram.sps@vistas.ac.in

Cite this paper as: S. Martin, I. Soma Sundaram, (2025) Gastro Retentive Drug Delivery Systems (Grdds)- Comprehensive Review. *Journal of Neonatal Surgery*, 14 (25s), 956-962.

ABSTRACT

Gastrointestinal transit time is a critical factor in the pharmacokinetics of many orally administered drugs. Conventional oral formulations often fail to maintain adequate plasma drug levels for extended periods, particularly for drugs with a narrow absorption window, poor solubility at higher pH, or those that are unstable in intestinal environments. GRDDS are specially engineered to address these limitations by remaining in the stomach for prolonged periods, thus ensuring consistent drug release and improved systemic absorption. Various technological strategies have been developed to achieve gastro retention, including floating systems that maintain buoyancy in gastric fluids, mucoadhesive formulations that bind to the stomach lining, expandable systems that resist gastric emptying by increasing in size, and high-density systems that sink and settle in the stomach. These systems must be optimized based on physiological parameters such as gastric pH, motility, and the presence of food, which can significantly affect their performance and therapeutic outcomes. Recent advancements in materials science, nanotechnology, and pharmaceutical engineering have led to the development of next-generation GRDDS with enhanced functionalities, such as targeted drug release, environmental responsiveness, and improved patient compliance. The integration of 3D printing technologies and intelligent polymers offers further potential for the personalization of GRDDS. This review critically examines these innovations and their implications for the future of oral drug delivery.

Keywords: *Gastro Retentive Drug Delivery System, Floating Drug Delivery, Bio adhesion, Gastric Residence Time, Controlled Release.*

1. INTRODUCTION

Oral drug delivery remains the most convenient and preferred route of administration due to its ease, non-invasiveness, and patient compliance. However, many drugs face challenges such as low bioavailability, short half-life, and poor absorption in the lower GIT. GRDDS offer a promising solution by extending the gastric retention time of drugs, thereby improving their absorption and efficacy.

Moreover, drugs that are absorbed in the upper part of the small intestine or require local action in the stomach particularly benefit from gastroretentive formulations. Without adequate gastric residence, such drugs may pass into the intestine too quickly, resulting in suboptimal therapeutic levels and reduced clinical effectiveness. GRDDS enable a more predictable and prolonged drug release pattern, which is especially critical for drugs with site-specific absorption [1].

The effectiveness of GRDDS depends on various design considerations, including the drug's physicochemical properties, the choice of polymers, and the intended release kinetics. Additionally, patient-specific factors such as posture, fed or fasted state, and gastric motility influence the performance of these systems. A deep understanding of these parameters is essential for the rational design of effective GRDDS, aimed at maximizing therapeutic outcomes while minimizing side effects and dosing frequency [2].

2. RATIONALE FOR GRDDS

Drugs with narrow absorption windows in the upper GIT, those that are locally active in the stomach, and those that degrade in alkaline pH benefit significantly from GRDDS. [3] Prolonged gastric retention ensures that the drug remains in the stomach for an extended period, leading to improved solubility and sustained release.

Additionally, GRDDS are particularly advantageous for drugs with low solubility in the intestinal environment but better solubility in acidic gastric fluids. By retaining the drug in the stomach, GRDDS promote higher dissolution rates and a greater concentration gradient for absorption [4]. Moreover, they facilitate the development of once-daily or reduced-frequency dosing regimens, which enhance patient adherence to treatment, especially for chronic therapies.

For drugs that act locally in the stomach, such as antacids, anti-ulcer agents, and antibiotics for Helicobacter pylori eradication, GRDDS provide targeted delivery and minimize systemic side effects. In the case of drugs with a short half-life, GRDDS help in maintaining a steady plasma concentration by ensuring continuous release from the stomach, thereby reducing fluctuations and improving therapeutic efficacy [5].

Furthermore, GRDDS are suitable for peptide and protein drugs that are susceptible to enzymatic degradation in the intestine. By formulating these drugs into GRDDS, it is possible to improve their stability and absorption. These benefits make GRDDS an essential platform in modern pharmaceutics for enhancing drug bioavailability, minimizing drug loss, and ensuring optimal clinical outcomes.

3. PHYSIOLOGY OF THE STOMACH AND FACTORS INFLUENCING GASTRIC RETENTION:

Key physiological factors influencing gastric retention include gastric pH, motility patterns, presence or absence of food, and nature of the dosage form [6]. The Migrating Myoelectric Complex (MMC) is a critical determinant of gastric emptying during fasting states. Fed states typically prolong gastric retention, making meal-timing a consideration in GRDDS administration.

Gastric emptying is a highly variable process influenced by the composition and volume of ingested food. High-fat and high-calorie meals tend to delay gastric emptying, which can enhance the retention time of gastroretentive formulations. In contrast, liquids and small particles are emptied rapidly from the stomach. Additionally, circadian rhythms and posture can influence gastric motility and emptying patterns, with reduced motility observed during nighttime [7].

The pH of the stomach is acidic (1.0 to 3.5) in fasting conditions and may rise transiently after meals. This pH fluctuation affects drug solubility and the swelling or dissolution behavior of polymers used in GRDDS [8]. Floating systems, for instance, rely on sufficient gas generation and buoyancy, which can be impacted by gastric pH and motility.

Furthermore, the gastric mucosa is covered by a mucus layer that renews periodically. Mucoadhesive systems must account for mucus turnover rates to maintain prolonged adhesion. Patient-specific variables such as age, gender, disease state (e.g., gastroparesis) , and concurrent medication use (e.g., anticholinergics, prokinetics) can also significantly affect gastric residence time. Hence, personalized GRDDS formulations may be necessary for optimal therapeutic outcomes.

Understanding these physiological parameters is crucial for designing GRDDS with predictable performance. Advanced imaging techniques such as scintigraphy and magnetic resonance imaging (MRI) are increasingly being used to assess gastric residence and transit behaviors of such formulations in vivo [9].

4. GRDDS APPROACHES:

4.1 Floating Drug Delivery Systems Floating systems have lower density than gastric fluids and float on the stomach content. These are classified into effervescent (e.g., sodium bicarbonate-based) and non-effervescent systems (e.g., hydrocolloids) [10–12]. These systems rely on generating sufficient buoyancy to remain afloat for a prolonged period. Effervescent systems create gas when they react with gastric fluid, while non-effervescent systems use swellable polymers to reduce density. Commonly used materials include HPMC, ethyl cellulose, and alginate. Innovations such as dual-layer tablets and floating microspheres have further enhanced the applicability and performance of these systems.

4.2 Mucoadhesive Systems These systems adhere to the gastric mucosa via bioadhesive polymers like chitosan and carbopol, resisting peristaltic movements and promoting longer retention [13,14]. The adhesion mechanism involves physical entanglement and chemical interactions such as hydrogen bonding. These systems may incorporate thiolated polymers that form disulfide bonds with mucosal surfaces, enhancing mucoadhesion. The effectiveness depends on the polymer's charge, molecular weight, and hydration characteristics. Mucoadhesive GRDDS can be formulated as tablets, gels, or patches, offering versatility in design.

4.3 Swelling and Expandable Systems These systems swell after ingestion to a size that resists gastric emptying. Polymers such as HPMC and xanthan gum are commonly used [15,16]. Upon contact with gastric fluid, they absorb water, expand in size, and form a gelatinous barrier that slows down transit. This expansion ensures that the dosage form remains too large to pass through the pylorus. These systems must strike a balance between rapid swelling and mechanical integrity to avoid premature expulsion. Recent advances include super-porous hydrogels and unfolding film systems designed for longer residence and better safety profiles.

4.4 High-Density Systems These dosage forms sink to the bottom of the stomach and remain there due to their density (>2.5 g/cm^3), which is greater than gastric fluids [16]. High-density systems are less influenced by gastric motility compared to floating systems. They often include inert materials such as barium sulfate, zinc oxide, or iron powder to achieve the desired

weight. These systems are particularly advantageous for drugs that require prolonged contact with gastric mucosa or are poorly soluble at higher pH levels. Their performance may still be affected by the fasted or fed state and formulation size, requiring careful optimization.

5. POLYMERS USED IN GRDDS:

A variety of natural and synthetic polymers are used in GRDDS:

Natural polymers include xanthan gum, guar gum, pectin, and sodium alginate. These are biodegradable, biocompatible, and often exhibit excellent swelling and gel-forming properties suitable for gastroretention.

Synthetic polymers such as hydroxypropyl methylcellulose (HPMC), Eudragit®, polyethylene oxide (PEO), and carbomers are widely used due to their reproducibility, controlled swelling behavior, and sustained release potential. HPMC, in particular, is extensively employed in floating and swelling systems for its hydrophilic matrix-forming ability [17].

Polymer selection depends on the drug properties, target release profile, desired mechanical strength, and gastric retention strategy. For example, mucoadhesive systems benefit from anionic polymers like carbopol due to their strong interaction with the mucosal lining. In contrast, floating systems require polymers that can retain entrapped gas or rapidly swell to reduce density.

Combinations of polymers are often utilized to optimize performance. For instance, blending HPMC with sodium bicarbonate enhances the floating ability, while incorporating chitosan improves adhesion. Advances in polymer modification, including thiolation or graft copolymerization, have also led to new materials with enhanced gastroretentive capabilities. These engineered polymers can provide multifunctional properties, enabling more sophisticated drug release profiles and better retention in the stomach [18].

6. EVALUATION OF GRDDS:

The successful development of gastroretentive drug delivery systems (GRDDS) requires thorough evaluation using both in vitro and in vivo methods to ensure effective gastric retention, controlled drug release, and enhanced bioavailability [19].

In Vitro Evaluation:

- **Buoyancy Studies:** Floating systems are evaluated for floating lag time (the time taken for the dosage form to rise to the surface) and total floating duration. This is typically conducted in simulated gastric fluid (SGF, pH 1.2) under controlled stirring conditions to mimic gastric motility. Longer floating duration indicates better potential for prolonged gastric retention.
- **Swelling Index:** Swelling studies measure the extent and rate at which polymers absorb gastric fluids and expand. This is critical for swelling and expandable systems. The swelling index is calculated by measuring the increase in weight or volume of the dosage form over time in SGF.
- **Mucoadhesion Strength:** For bioadhesive systems, adhesion strength to gastric mucosa is assessed using texture analyzers or modified balance methods. Parameters such as detachment force and residence time on mucosal tissue provide insights into the adhesive performance of polymers.
- **Drug Release Kinetics:** Drug dissolution is studied using USP apparatus (typically paddle or basket) in SGF to simulate gastric conditions. The release profile is analyzed with kinetic models such as zero-order (constant release), first-order (concentration-dependent release), Higuchi (diffusion-based release), and Korsmeyer–Peppas (to identify release mechanisms). This helps predict in vivo behavior and optimize formulation parameters.
- **Mechanical Strength and Integrity:** For expandable and swelling systems, mechanical testing ensures the dosage form can withstand gastric contractions without premature disintegration or obstruction risk.

In Vivo Evaluation:

- **Imaging Techniques:**
    - **Gamma Scintigraphy:** Widely regarded as the gold standard, this involves labeling the dosage form with a gamma-emitting radionuclide (e.g., Technetium-99m) to non-invasively track its transit and retention time in the gastrointestinal tract using a gamma camera.
    - **X-Ray Imaging:** Dosage forms embedded with radiopaque markers like barium sulfate or titanium dioxide allow visualization under X-ray. This method is less sensitive than scintigraphy but useful for qualitative assessment.
    - **Magnetic Resonance Imaging (MRI):** MRI provides high-resolution images without ionizing radiation, enabling detailed observation of dosage form location, swelling behavior, and interactions with gastric tissues.

    - **Ultrasound Imaging:** Emerging as a non-invasive technique to study gastric retention and motility effects, though limited by resolution and operator dependency [20].

- **Pharmacokinetic Studies:** Measurement of plasma drug concentration-time profiles following administration provides direct evidence of improved bioavailability and controlled release. Key parameters such as C_max, T_max, and AUC are compared with conventional dosage forms.
- **Animal Models:** Animal studies (e.g., in dogs, rabbits, or pigs) are essential for preliminary validation of gastric retention and release profiles, especially since animal gastric physiology varies [21]. These studies help optimize formulation prior to human trials.
- **Human Volunteer Studies:** Clinical studies under fed and fasted conditions assess the effect of meal timing and food composition on gastric retention and drug absorption. Variables such as patient posture and activity level may also be investigated.
- **Additional Evaluations:**
    - **Gastrointestinal Transit Time:** Measured using breath tests or capsule endoscopy to correlate retention with drug release.
    - **Safety Assessments:** Evaluations for potential gastric irritation, obstruction risk, and toxicity related to excipients or polymers.

7. RECENT ADVANCES:

Recent years have witnessed significant progress in the design and development of GRDDS, leveraging cutting-edge technologies and novel materials to overcome traditional limitations and enhance therapeutic efficacy [22].

Nanoparticle-loaded GRDDS: The incorporation of nanoparticles within GRDDS has emerged as a powerful strategy to improve the solubility and bioavailability of poorly water-soluble drugs. Nanocarriers such as lipid-based nanoparticles, solid lipid nanoparticles (SLNs), and polymeric nanoparticles offer protection against enzymatic degradation and allow for controlled, sustained release. These nanosystems can be engineered to target specific gastric sites, enhancing localized drug action and reducing systemic side effects. Additionally, nanoparticles can modulate drug release kinetics by controlling the interaction between the drug and the polymer matrix within the gastroretentive system.

3D Printing Technologies: The advent of additive manufacturing has revolutionized oral drug delivery by enabling the fabrication of complex and patient-specific gastroretentive dosage forms, often referred to as “printlets.” 3D printing allows precise control over internal geometry, porosity, and drug distribution, which directly influence buoyancy and drug release profiles. Novel designs such as multi-layered or compartmentalized printlets can combine immediate and sustained release properties within a single dosage form. Moreover, 3D printing facilitates rapid prototyping and personalized medicine by tailoring dose and release characteristics based on individual patient needs [23].

Smart Polymers: Stimuli-responsive or “smart” polymers represent an innovative class of materials that respond dynamically to physiological triggers such as pH changes, temperature shifts, or enzymatic activity. Thermo-responsive polymers, like poloxamers, can undergo sol-gel transitions at body temperature, enabling in situ gel formation in the stomach. pH-sensitive polymers can alter their swelling or adhesive properties in response to the acidic gastric environment, improving retention and targeted drug release. Enzyme-responsive systems are also under exploration, where polymer degradation or drug release is triggered by specific gastric enzymes, allowing more precise control over therapeutic timing.

Gastroretentive Films and Microparticles: Thin gastroretentive films and microparticles provide novel dosage forms that combine extended mucosal adhesion with controlled drug release. Films can be designed to rapidly adhere to the gastric lining, releasing the drug directly at the site of action while minimizing dose variability caused by gastric emptying. Microparticles, including microspheres and microcapsules, offer advantages such as uniform size distribution, ease of swallowing, and improved patient compliance. Advances in microencapsulation techniques and coating materials have enhanced the stability and retention of these systems in the acidic gastric environment.

Other Emerging Technologies:

- **Magnetic Systems:** Incorporation of magnetic materials within dosage forms allows external control of gastric retention using applied magnetic fields. These systems are being explored for site-specific targeting and prolonged gastric residence.
- **Ultrasound-Responsive Systems:** Experimental GRDDS responsive to ultrasound waves can modulate drug release remotely, providing on-demand therapy and improved patient compliance.
- **Biodegradable Gastroretentive Devices:** Advances in biodegradable polymers have enabled the design of expandable or shape-memory devices that swell or unfold after ingestion and safely degrade after completing their

drug release, reducing the risk of gastric obstruction.

Overall, these advancements underscore a multidisciplinary approach combining materials science, nanotechnology, and engineering to enhance the functionality, safety, and patient-centered design of GRDDS. Continued innovation promises to expand the scope of gastroretentive therapies to a broader range of drugs and clinical conditions.

8. CLINICAL AND COMMERCIAL APPLICATIONS:

Gastro Retentive Drug Delivery Systems (GRDDS) have made significant strides from research laboratories to commercial pharmaceutical products, demonstrating their potential to improve therapeutic efficacy and patient compliance. Several GRDDS formulations are currently marketed, and many more are in various stages of clinical development.

Commercially Available Products:

- **Madopar® HBS (Levodopa + Benserazide):** Madopar® HBS (Hydrodynamically Balanced System) is a well-established floating dosage form designed for Parkinson's disease management. By prolonging gastric retention, it ensures a steady release of levodopa and benserazide, enhancing absorption in the upper gastrointestinal tract and reducing the fluctuations in plasma drug concentration. This results in more consistent symptom control and improved patient quality of life compared to immediate-release formulations.
- **Cifran® OD (Ciprofloxacin):** Cifran® OD is a floating drug delivery system for ciprofloxacin, an antibiotic used to treat urinary tract infections and other bacterial infections. The gastroretentive formulation maintains the drug in the stomach for an extended period, improving its absorption and bioavailability. This controlled release helps maintain therapeutic levels for longer durations, potentially reducing dosing frequency and side effects.

Other Notable Examples:

- **Valrelease® (Diazepam):** A floating tablet designed to prolong gastric residence time for diazepam, providing sustained anxiolytic effects.
- **Gastrozep® (Baclofen):** Developed to improve the local delivery and absorption of baclofen for spasticity, leveraging mucoadhesive and floating properties.
- **Controlled Release Tablets for Famotidine and Metformin:** Several formulations designed to extend gastric retention and improve the bioavailability of these drugs, particularly beneficial for drugs with narrow absorption windows [24].

Clinical Benefits of GRDDS:

- **Improved Bioavailability and Therapeutic Efficacy:** By ensuring prolonged drug presence in the stomach, GRDDS improve absorption of drugs with narrow absorption windows, enhancing clinical outcomes.
- **Reduced Dosing Frequency:** Sustained drug release reduces the need for frequent dosing, which can improve patient adherence, especially in chronic conditions.
- **Localized Treatment:** GRDDS are particularly advantageous for treating gastric disorders, such as Helicobacter pylori infections, by maintaining therapeutic drug concentrations at the site of infection.
- **Reduced Side Effects:** Controlled and site-specific drug release minimizes systemic exposure and associated adverse effects.

Challenges and Future Directions:

Despite their advantages, the commercial translation of GRDDS faces challenges such as variability in gastric retention due to physiological factors, complexity in manufacturing, and regulatory hurdles. Advances in polymer science, nanotechnology, and personalized medicine are expected to overcome these barriers, enabling more effective and patient-friendly GRDDS.

Ongoing clinical trials continue to explore GRDDS for a variety of therapeutic agents, including peptides, proteins, and poorly soluble drugs, broadening their application scope. Integration with novel technologies like 3D printing and smart polymers holds promise for customized and responsive drug delivery solutions tailored to individual patient needs.

In conclusion, the commercial success of existing GRDDS products underscores the clinical potential of this drug delivery approach. With continued innovation, GRDDS are poised to play an increasingly important role in modern pharmaceutics, offering enhanced therapeutic outcomes and improved patient quality of life.

9. CONCLUSION:

Gastro Retentive Drug Delivery Systems (GRDDS) have emerged as a transformative approach in oral drug delivery, specifically addressing the challenges posed by drugs with narrow absorption windows, poor solubility, and instability in the

intestinal environment. By prolonging the gastric residence time, these systems enhance drug bioavailability, provide controlled and sustained release, and improve therapeutic outcomes. Their ability to localize drugs in the stomach also offers targeted treatment options for gastric ailments, highlighting their clinical significance.

The ongoing advancements in polymer science, nanotechnology, and formulation techniques continue to expand the potential of GRDDS. Innovative materials such as smart polymers and nanoparticle integrations, alongside cutting-edge manufacturing technologies like 3D printing, are enabling the development of highly customizable and efficient gastroretentive formulations. These advancements not only improve drug stability and release profiles but also enhance patient compliance through reduced dosing frequency and improved ease of administration.

Despite the promising progress, challenges such as inter-patient variability, physiological constraints, and regulatory considerations remain. Addressing these hurdles through rigorous research, optimized design strategies, and collaborative regulatory frameworks will be critical for the successful translation of GRDDS into widespread clinical practice. With sustained innovation and interdisciplinary efforts, GRDDS are poised to play a pivotal role in the future of oral drug delivery, offering safer, more effective, and patient-centric therapeutic options.

REFERENCES

[1] Streubel A, Siepmann J, Bodmeier R. Floating matrix tablets based on low-density foam powder: effects of formulation and processing parameters. Int J Pharm. 2003.

[2] Whitehead L, Fell JT, Collett JH. Floating dosage forms: an in vivo study demonstrating prolonged gastric retention. J Control Release. 1998.

[3] Arora S, Ali J, Ahuja A, Khar RK, Baboota S. Floating drug delivery systems: a review. AAPS PharmSciTech. 2005.

[4] Talukder R, Fassihi R. Gastroretentive delivery systems: a mini review. Drug Dev Ind Pharm. 2004.

[5] Hwang SJ, Park H, Robinson JR. Gastric retentive drug delivery systems. Crit Rev Ther Drug Carrier Syst. 1998.

[6] Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F. Gastroretentive dosage forms: Overview and special case of Helicobacter pylori. J Control Release. 2006.

[7] Yuveraj Singh Tanwar. Floating drug delivery system: An overview. Int J PharmTech Res. 2011.

[8] Deshpande AA, Shah NH, Rhodes CT, Malick AW. Development of a novel controlled-release system for gastric retention. Pharm Res. 1997.

[9] Rouge N, Buri P, Doelker E. Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery. Int J Pharm. 1996.

[10] Chien YW. Novel Drug Delivery Systems. 2nd ed. 1992.

[11] Singh BN, Kim KH. Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention. J Control Release. 2000.

[12] Pawar VK, Kansal S, Asthana S, Chourasia MK. Industrial perspective of gastroretentive drug delivery systems: physicochemical, biopharmaceutical, technological and regulatory considerations. Expert Opin Drug Deliv. 2012.

[13] Lehr CM, et al. Bioadhesive drug delivery systems: a novel approach for controlled drug delivery. Pharm Ind. 1992.

[14] Andrews GP, Laverty TP, Jones DS. Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm. 2009.

[15] Garg R, Gupta GD. Progress in controlled gastroretentive delivery systems. Trop J Pharm Res. 2008.

[16] Streubel A, Siepmann J, Bodmeier R. Gastroretentive drug delivery systems. Expert Opin Drug Deliv. 2006.

[17] Ichikawa M, et al. A new multiple-unit oral floating dosage system II: in vivo evaluation of floating and sustained-release characteristics. J Pharm Sci. 1991.

[18] Billa N, Yuen KH, Peh KK, Wong TW. Formulation variables affecting drug release from xanthan gum matrices at laboratory scale and pilot scale. AAPS PharmSciTech. 2000.

[19] Patel A, Ray S, Thakur RS. In vitro evaluation and optimization of controlled release floating drug delivery system of metformin hydrochloride. DARU. 2006.

[20] Singh BN, Kim KH. Drug delivery: oral route. In: Encyclopedia of Pharmaceutical Technology. 2007.

[21] Khan MA, et al. Gastroretentive drug delivery systems: a patent perspective. Int J Health Res. 2009.

[22] Sabzevari A, et al. pH-responsive and gastroretentive controlled release floating tablets for oral delivery of ranitidine hydrochloride. Iran J Pharm Res. 2014.

[23] Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers. Adv Drug Deliv Rev. 2012.

[24] Rouge N, et al. Comparative pharmacokinetic study of a floating multiple-unit capsule and an immediate-release tablet of madopar in humans. Pharm Res. 1998.